ANXA2
ATC code L01
Abemaciclib
Acalabrutinib
Adagrasib
Adipotide
Afatinib
Aflibercept
Alectinib
Alemtuzumab
Alpelisib
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Angiogenesis
Anti-cancer medication
Antineoplastic
Asciminib
Astex Pharmaceuticals
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
BRAF (gene)
Baricitinib
Bcr-abl fusion protein
Belantamab mafodotin
Bermekimab
Bevacizumab
Binimetinib
Bladder cancer
Blinatumomab
Bosutinib
Breakthrough therapy
Brentuximab vedotin
Brigatinib
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
Cabozantinib
Cancer immunotherapy
Capmatinib
Catumaxomab
Cediranib
Cell differentiation
Cemiplimab
Ceritinib
Cetuximab
ChEMBL
ChemSpider
Chemical formula
Cholangiocarcinoma
ClinicalTrials.gov
Cobimetinib
Committee for Medicinal Products for Human Use
CompTox Chemicals Dashboard
Copanlisib
Cosibelimab
Crizotinib
Dabrafenib
Dacomitinib
DailyMed
Dalpiciclib
Daratumumab
Dasatinib
Denileukin diftitox
Dinutuximab beta
Doi (identifier)
Dostarlimab
DrugBank
Drug class
Drug development
Drug discovery
Drug nomenclature
Drugs.com
Durvalumab
Duvelisib
ECHA InfoCard
EML4
Edrecolomab
Elotuzumab
Elranatamab
Encorafenib
Enfortumab vedotin
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib (data page)
Erlotinib
Esophageal cancer
European Medicines Agency
Everolimus
Exotoxin
Fedratinib
Fibroblast growth factor receptor
Filgotinib
First-in-class medication
Food and Drug Administration
Fruquintinib
Fusion protein
Futibatinib
Gastric cancer
Gefitinib
Gemtuzumab ozogamicin
Gilteritinib
Glasdegib
Glofitamab
HER2/neu
Hdl (identifier)
Health Canada
Hedgehog signaling pathway
IUPAC nomenclature of chemistry
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Idelalisib
Imatinib
Inavolisib
Indicated
Infigratinib
Inotuzumab ozogamicin
Interleukin 2
International Chemical Identifier
Ipilimumab
Isatuximab
JSmol
Janssen Pharmaceuticals
Janus kinase
KEGG
KRAS
Lapatinib
Larotrectinib
Lazertinib
Lenvatinib
Lestaurtinib
Leukemia
Loncastuximab tesirine
Lorlatinib
Lymphatic system
Lymphoma
MEN1
MTOR inhibitor
Masitinib
MedlinePlus
Midostaurin
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody therapy
Mosunetuzumab
Moxetumomab pasudotox
Myeloid
Naxitamab
Necitumumab
Neratinib
Nilotinib
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Non-small cell lung cancer
Obinutuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Oportuzumab monatox
Oral administration
Orelabrutinib
Osimertinib
PMID (identifier)
Pacritinib
Palbociclib
Panitumumab
Parsaclisib
Pazopanib
Pembrolizumab
Pemigatinib
Pertuzumab
Pexidartinib
Pi3K inhibitor
Pirtobrutinib
Platelet-derived growth factor receptor
Polatuzumab vedotin
Ponatinib
Pralsetinib
Prescription drug
Proapoptotic
Prohibitin
Prolgolimab
PubChem
Public domain
Quizartinib
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Repotrectinib
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Ripretinib
Rituximab
Rociletinib
Route of administration
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Selpercatinib
Selumetinib
Semaxanib
Serplulimab
Simplified molecular-input line-entry system
Sirolimus
Sonidegib
Sorafenib
Sotorasib
Src (gene)
Sugemalimab
Sunitinib
Tafasitamab
Talquetamab
Targeted cancer therapy
Tarlatamab
Tebentafusp
Teclistamab
Temsirolimus
Tepotinib
Tislelizumab
Tisotumab vedotin
Tivozanib
Toceranib
Toripalimab
Tositumomab
Trametinib
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trilaciclib
Tucatinib
Tyrosine kinase inhibitor
Tyrosine kinases
Unique Ingredient Identifier
Urothelial cancer
VEGF receptors
Vandetanib
Vascular endothelial growth factor
Vascular endothelial growth factor A
Vemurafenib
Venetoclax
Vismodegib
Zanidatamab
Zanubrutinib
Zenocutuzumab
Zolbetuximab